Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

1079b340c43662c4c007cc99c6e7c9fd332b4755e31f468dcc7c1dc97036f84c

Total Revenue (USD, thousands)

Cost of Goods Sold (COGS) (USD, thousands)

SG&A (USD, thousands)

R&D (USD, thousands)

D&A (USD, thousands)

Interest Expense (USD, thousands)

Operating Income (EBIT) (USD, thousands)

Net Income (USD, thousands)

EPS - Basic (USD)

EPS - Diluted (USD)

27f415f675a6a301392a48ae8a8ea84bee9f716b10d6fbbe5f61de1d6ba83e0b

Current Assets (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable (USD, thousands)

Inventory (USD, thousands)

Non-Current Assets (USD, thousands)

Property, Plant, and Equipment (PP&E) (USD, thousands)

Goodwill (USD, thousands)

Intangible Assets (USD, thousands)

Current Liabilities (USD, thousands)

Accounts Payable (USD, thousands)

Short-term Debt (USD, thousands)

Accrued Expenses (USD, thousands)

Non-Current Liabilities (USD, thousands)

Long-term Debt (USD, thousands)

Lease Liabilities (USD, thousands)

Deferred Tax Liabilities (USD, thousands)

Shareholders' Equity (USD, thousands)

Retained Earnings (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

09f15624d887e2074a9486d86e9d34b4c331ccdd89af7fb08ef2b349c6310ac5

Clinical half-life for ORIC-944 (hour)

Provisional recommended Phase 2 dose for ORIC-114 (80 mg QD) (mg QD)

Provisional recommended Phase 2 dose for ORIC-114 (120 mg QD) (mg QD)

70873a01c2ade82d1249aebd34c77fbe4b6b98d9e761a2070a56c1cb656c1b07

Cash and cash equivalents (USD, thousands)

Short-term investments (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Long-term investments (USD, thousands)

Property and equipment, net (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Other long-term liabilities (USD, thousands)

Total liabilities (USD, thousands)

Preferred stock (USD, thousands)

Common stock (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Accumulated other comprehensive income (USD, thousands)

Total stockholders' equity (USD, thousands)

Total liabilities and stockholders' equity (USD, thousands)

c74ed078436bdc49cdc1bcb1f96449de05e381819aa104699c8c7649dc30b4b0

Net loss [USD, thousands]

Depreciation [USD, thousands]

Stock-based compensation expense [USD, thousands]

Loss on fixed asset disposals [USD, thousands]

Accretion of discount on investments, net [USD, thousands]

Net cash used in operating activities [USD, thousands]

Acquisitions of property and equipment [USD, thousands]

Purchases of investments [USD, thousands]

Maturities of investments [USD, thousands]

Net cash used in investing activities [USD, thousands]

Proceeds from issuance of common stock and pre-funded warrants [USD, thousands]

Issuance costs associated with financings [USD, thousands]

Proceeds from issuance of common stock under ESPP [USD, thousands]

Proceeds from stock option exercises [USD, thousands]

Net cash provided by financing activities [USD, thousands]

Net increase (decrease) in cash, cash equivalents and restricted cash [USD, thousands]

Prepaid expenses and other assets [USD, thousands]

Accounts payable and accrued other liabilities [USD, thousands]

Cash, cash equivalents and restricted cash at beginning of period [USD, thousands]

Cash, cash equivalents and restricted cash at end of period [USD, thousands]

1242c892185237632ccc6f005eecade4e21aa6762b6483b237930b08b1a5b11a

Research and Development Expenses (USD, thousands)

General and Administrative Expenses (USD, thousands)

Total Operating Expenses (USD, thousands)

Loss from Operations (USD, thousands)

Other Income, Net (USD, thousands)

Net Loss (USD, thousands)

Unrealized Gain (Loss) on Investments (USD, thousands)

Comprehensive Loss (USD, thousands)

Net Loss per Share, Basic and Diluted (USD)

Weighted-average Shares Outstanding, Basic and Diluted

1d6cff42b38663282e9e92a5d71df236e2a56d36ce424eb9475685c826e7410d

Oric Pharmaceuticals (ORIC)

Financials